Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Adult and pediatric subjects (greater than or equal to 13 years of age and greater than or equal to 49 kg)~* Be registered to an NIH protocol that includes bone marrow, cord, haplo-cord or peripheral blood stem cell transplantation~* Have GI GVHD as determined by the medical team that requires treatment with budesonide and systemic corticosteroids (e.g. methylprednisolone or prednisone)~* Be candidates for antifungal therapy~* Liver function tests:~  * Alanine aminotransferase (ALT) must be \<5 times the upper limit of normal (ULN)~ * Aspartate aminotransferase (AST) must be \<5 times ULN~EXCLUSION CRITERIA:~* Pregnant or breast-feeding~* Prohibited drugs~  --Note: Treatment with corticosteroids and/or immunosuppressants is permitted~* Consumption of grapefruit juice or grapefruit in the past seven days prior to study enrollment~* Inability to take oral medications~* Allergy(ies) to budesonide, fluconazole, micafungin, voriconazole~* ECOG performance status greater than or equal to 4 (adults and children 16 years and older) or Lansky perfomance status less than or equal to 30 (children\< 16 years old)~* Psychiatric disorder or mental deficiency that could interfere with the subject s ability to comply with study procedures and requirements~* Inability to provide informed consent~* Major anticipated illness or organ failure whereby the subject s anticipated survival within 2 weeks is unlikely (PI discretion)~* Current documented or suspected invasive fungal infection~* Intensive care unit (ICU) patient~* Child-Pugh Class C hepatic impairment~* AST greater than or equal to 5 times ULN, ALT greater than or equal to 5 times ULN~* Contraindication to an azole as determined by research team~* Body weight \< 49 kg at the time of study enrollment

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): subjects may be on fluconazole or micafungin at study entry or be on no antifungal prophylaxis.
- Cohort 2 (Type: EXPERIMENTAL): subjects are on voriconazole at study entry. Voriconazole will continue throughout days O to 7.
- Cohort 3 (Type: EXPERIMENTAL): subjects are on fluconazole at study entry. Fluconazole will continue throughout days O to 7.

Based on this trial design, predict the completion outcome and termination type (if applicable).